Literature DB >> 24651909

Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.

Giulio Rossi1, Alberto Cavazza2, Luisella Righi3, Giuliana Sartori1, Alessandra Bisagni2, Lucia Longo4, Giuseppe Pelosi5, Mauro Papotti6.   

Abstract

Pulmonary mucin-producing adenocarcinomas may be indistinguishable on conventional histology from a metastasis, as thyroid transcription factor-1 (TTF-1) expression often is lacking and KRAS mutations are widely present even in extrapulmonary sites. Few data have been reported on the diagnostic role of napsin-A and epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene alterations in this challenging differential diagnosis. Seventy-seven surgically resected cases, including 53 primary and 24 metastatic tumors from different sites, were evaluated for napsin-A, TTF-1, and ALK by immunohistochemistry and for EGFR mutations by direct sequencing. Overall, napsin-A expression in primary lung mucin-producing adenocarcinomas was 36% (8% mucinous, 17% colloid, 87.5% solid, and 100% signet ring cell) and TTF-1 expression reached an overall figure of 42% (12.5% mucinous, 33% colloid, 87.5% solid, and 100% signet ring cell). Metastatic mucinous adenocarcinomas did not react with napsin-A or with TTF-1. All primary and metastatic tumors lacked EGFR mutations, while a single case of signet ring cell lung adenocarcinoma showed ALK expression and rearrangement at fluorescent in situ hybridization analysis. Napsin-A has a lower sensitivity compared with TTF-1 in primary mucin-producing adenocarcinomas of the lung. However, both antibodies have an absolute specificity, being always negative in metastatic mucinous adenocarcinomas. EGFR mutations and ALK translocation or expression are exceedingly rare in mucin-producing adenocarcinomas of the lung, resulting unnecessary as diagnostic tool in this setting.
© The Author(s) 2014.

Entities:  

Keywords:  EGFR; TTF-1; adenocarcinoma; immunohistochemistry; lung; metastasis; mucinous; napsin-A

Mesh:

Substances:

Year:  2014        PMID: 24651909     DOI: 10.1177/1066896914527609

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  4 in total

1.  Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma.

Authors:  Angelica Sonzogni; Fabrizio Bianchi; Alessandra Fabbri; Mara Cossa; Giulio Rossi; Alberto Cavazza; Elena Tamborini; Federica Perrone; Adele Busico; Iolanda Capone; Benedetta Picciani; Barbara Valeri; Ugo Pastorino; Giuseppe Pelosi
Journal:  J Pathol Clin Res       Date:  2017-03-22

2.  Synchronous mucinous and non-mucinous lung adenocarcinomas with different epidermal growth mutational status.

Authors:  Rita Linhas; David Tente; Margarida Dias; Ana Barroso
Journal:  Respir Med Case Rep       Date:  2017-06-03

Review 3.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

4.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.